CEO Eric Easom was paid $1,382,985 in fiscal year 2025, ↓ down 17.0% from fiscal year 2024 (SEC filing 0001193125-26-170314 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,382,985 ↓ Eric Easom total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ANTX's next annual pay disclosure, estimated May 4, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Easom | $603,750 | $0 | $164,133 | $275,539 | $332,063 | $0 | $7,500 | $1,382,985 |
| President, Chief Executive Officer and Board Chair | ||||||||
| Josh Eizen | 450,000 | 0 | 66,105 | 110,975 | 180,000 | 0 | 0 | 807,080 |
| Chief Legal Officer and Chief Operating Officer | ||||||||
| Lucy Day | 447,200 | 0 | 52,545 | 88,211 | 178,880 | 0 | 7,500 | 774,336 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Eric Easom | $1,382,985 | $1,666,117 | $3,342,848 | ↓ −283,132 |
| Josh Eizen | 807,080 | 1,057,350 | 1,147,944 | ↓ −250,270 |
| Lucy Day | 774,336 | 812,699 | 1,524,458 | ↓ −38,363 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read AN2 Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ANTX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ANTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ANTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Eric Easom | CEO | $1,382,985 |
| Josh Eizen | COO | $807,080 |
| Lucy Day | CFO | $774,336 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Gilbert Lynn Marks, M.D | Independent Director | $57,904 |
| Joseph Zakrzewski | Independent Director | $71,893 |
| Kabeer Aziz | Independent Director | $57,904 |
| Margaret FitzPatrick | Lead Independent Director | $89,393 |
| Melvin Spigelman, M.D | Independent Director | $67,893 |
| Patricia Martin | Independent Director | $72,240 |
| Rob Readnour, Ph.D | Independent Director | $68,393 |
| Stephanie Wong | Independent Director | $79,393 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lucy Day | RSU | 46,500 | — | $53,010 |
| Eric Easom | Option | 223,928 | 1.13 | — |
| Josh Eizen | RSU | 45,000 | — | 51,300 |
| Josh Eizen | RSU | 58,500 | — | 66,690 |
| Eric Easom | Option | 72,489 | 11.99 | — |
| Josh Eizen | Option | 31,251 | 3 | — |
| Lucy Day | Option | 71,677 | 1.13 | — |
| Eric Easom | Option | 103,125 | 3 | — |
| Eric Easom | Option | 14,063 | 17.28 | — |
| Eric Easom | RSU | 74,250 | — | 84,645 |
| Josh Eizen | Option | 45,938 | 1.08 | — |
| Lucy Day | RSU | 36,578 | — | 0 |
| Eric Easom | RSU | 145,250 | — | 165,585 |
| Josh Eizen | RSU | 23,625 | — | 26,933 |
| Josh Eizen | RSU | 22,500 | — | 25,650 |
| Lucy Day | RSU | 20,625 | — | 23,513 |
| Josh Eizen | Option | 17,250 | 17.88 | — |
| Josh Eizen | Option | 13,583 | 14.29 | — |
| Josh Eizen | Option | 90,188 | 1.13 | — |
| Lucy Day | RSU | 8,837 | — | 0 |
| Lucy Day | RSU | 22,588 | — | 0 |
| Lucy Day | Option | 4,125 | 17.28 | — |
| Lucy Day | Option | 22,290 | 14.29 | — |
| Lucy Day | Option | 28,646 | 3 | — |
Compensation is designed to align executive interests with stockholders, motivate short- and long-term results, and reflect market practices for comparable positions.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | — | — | — | — | — |
| 2025 | 2025-05-22 | — | — | — | — | — |
| 2024 | 2024-06-19 | — | — | — | — | — |
| 2023 | 2023-06-07 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | —a |
| 2025 | 2025-05-22 | —b |
| 2024 | 2024-06-19 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Margaret FitzPatrickIndependent · Lead Independent Director · Nominating and Corporate Governance | $69,000 | $0 | $20,393 | — | — | $89,393 |
| Stephanie WongIndependent · Audit (Chair) · Nominating and Corporate Governance | 59,000 | 0 | 20,393 | — | — | 79,393 |
| Patricia MartinIndependent · Compensation (Chair) | 51,250 | 597 | 20,393 | — | — | 72,240 |
| Joseph ZakrzewskiIndependent · Audit · Nominating and Corporate Governance | 51,500 | 0 | 20,393 | — | — | 71,893 |
| Rob Readnour, Ph.DIndependent · Nominating and Corporate Governance (Chair) | 48,000 | 0 | 20,393 | — | — | 68,393 |
| Melvin Spigelman, M.DIndependent · Compensation | 47,500 | 0 | 20,393 | — | — | 67,893 |
| Kabeer AzizIndependent · Audit | 35,625 | 1,886 | 20,393 | — | — | 57,904 |
| Gilbert Lynn Marks, M.DIndependent · Compensation | 35,625 | 1,886 | 20,393 | — | — | 57,904 |
| Eric EasomEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $104,546 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $397,500 |
| Equity awards (grant-date value) | $4,369 |
| All other compensation | $0 |
| Total cost of the board | $401,869 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AN2 Therapeutics | 2025 | Eric Easom | $603,750 | $164,133 | $275,539 | $332,063 | $1,382,985 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Eric Easom | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Executive Compensation”. As printed: 1,382,985. Filing ↗machine: r2 · c25 · span 352697–352706 |
| 2 | Section 01, Josh Eizen | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Executive Compensation”. As printed: 807,080. Filing ↗machine: r4 · c25 · span 372599–372606 |
| 3 | Section 01, Lucy Day | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Executive Compensation”. As printed: 774,336. Filing ↗machine: r6 · c25 · span 392493–392500 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-17 | 0001193125-26-110693 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Margaret FitzPatrick | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 89,393. Filing ↗machine: span 793821–794047 |
| 6 | Section 08, Stephanie Wong | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 79,393. Filing ↗machine: span 825063–825289 |
| 7 | Section 08, Patricia Martin | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 72,240. Filing ↗machine: span 806324–806550 |
| 8 | Section 08, Joseph Zakrzewski | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 71,893. Filing ↗machine: span 831308–831534 |
| 9 | Section 08, Rob Readnour, Ph.D | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 68,393. Filing ↗machine: span 812571–812797 |
| 10 | Section 08, Melvin Spigelman, M.D | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 67,893. Filing ↗machine: span 818821–819047 |
| 11 | Section 08, Kabeer Aziz | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 57,904. Filing ↗machine: span 787573–787799 |
| 12 | Section 08, Gilbert Lynn Marks, M.D | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 57,904. Filing ↗machine: span 800078–800304 |
| 13 | Section 08, Eric Easom | DEF 14A | 2026-04-22 | 0001193125-26-170314 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0001193125-26-262264 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 06, 2025 vote | Form 8-K | 2025-05-27 | 0001193125-25-127595 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 16 | Section 06, 2024 vote | Form 8-K | 2024-06-24 | 0001193125-24-166938 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 09b board cost (computed) | Computed | — | — | Cash 397,500 + equity 4,369 + all other 0 = 401,869, summed across the director compensation table rows.machine: formula: Σ = 401,869 |
| 19 | AN2 Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170314 | CEO total compensation as printed in AN2 Therapeutics's own proxy. As printed: 1,382,985. Filing ↗machine: r2 · c25 · span 352697–352706 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.